Table 5 Characteristics classified by pathological response

Age

0.001

0.011

 ≥ 65

 < 65

20

7

16

32

27

18

9

21

Sex

1

0.931

 Male

 Female

25

2

44

4

42

3

27

3

Smoking status

0.767

0.819

 Current or former smoker

 Never smoked

25

2

42

6

41

4

26

4

Location

0.604

0.209

 LU

 LL

 RU

 RM

 RL

10

2

8

2

5

13

7

17

1

10

18

4

12

2

9

5

5

13

1

6

lober atelectasis

0.436

0.298

 Yes

 No

2

25

8

40

4

41

6

24

Stage at baseline

0.76

0.784

 IIb

 IIIa

 IIIb

10

14

3

14

27

7

15

25

5

9

16

5

Tumor stage

0.899

0.512

 T1

 T2

 T3

11

12

4

17

23

8

19

20

6

9

15

6

Nodal stage

0.407

0.488

 N1

 N2

11

16

15

33

17

28

9

21

Nodal positive

0.265

0.036

 Multiple

 Single

4

23

14

34

7

38

11

19

Histology

0.081

0.039

 Adenocarcinoma

 Squamous-cell carcinoma

2

25

13

35

5

40

10

20

Differentiation degree

0.083

0.059

 Poor

 Moderate or well

9

18

26

22

17

28

18

12

Immunotherapy

0.707

0.919

 tislelizumab

 pembrolizumab

18

9

34

14

31

14

21

9

Neo-adjuvant doses

0.88

0.992

 2

 3

 4

20

5

2

38

7

3

35

7

3

23

5

2